Literature DB >> 10187204

The distribution of health care costs and their statistical analysis for economic evaluation.

A Briggs1, A Gray.   

Abstract

OBJECTIVE: Where patient level data are available on health care costs, it is natural to use statistical analysis to describe the differences in cost between alternative treatments. Health care costs are, however, commonly considered to be skewed, which could present problems for standard statistical tests. This review examines how authors report the distributional form of health care cost data and how they have analysed their results.
METHOD: A review of cost-effectiveness studies that collected patient-level data on health care costs. To supplement the review, five datasets on health care costs are examined. Consideration is given to the use of parametric methods on the transformed scale and to non-parametric methods of analysing skewed cost data.
RESULTS: Since economic analysis requires estimation in monetary units, the usefulness of transformation-based methods is limited by the inability to retransform cost differences to the original scale. Non-parametric rank sum methods were also found to be of limited use for economic analysis, partly due to the focus on hypothesis testing rather than estimation. Overall, the non-parametric approach of bootstrapping was found to offer a useful test of the appropriateness of parametric assumptions and an alternative method of estimation where those assumptions were found not to hold.
CONCLUSIONS: Guidelines for the analysis of skewed health care cost data are offered.

Entities:  

Mesh:

Year:  1998        PMID: 10187204     DOI: 10.1177/135581969800300410

Source DB:  PubMed          Journal:  J Health Serv Res Policy        ISSN: 1355-8196


  61 in total

Review 1.  How should cost data in pragmatic randomised trials be analysed?

Authors:  S G Thompson; J A Barber
Journal:  BMJ       Date:  2000-04-29

2.  Economic evaluation and clinical trials: size matters.

Authors:  A Briggs
Journal:  BMJ       Date:  2000-12-02

Review 3.  Handling uncertainty in cost-effectiveness models.

Authors:  A H Briggs
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

4.  Use of randomised controlled trials for producing cost-effectiveness evidence: potential impact of design choices on sample size and study duration.

Authors:  Martin E Backhouse
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

5.  Advantages of laparoscopic resection for ileocolic Crohn's disease. Improved outcomes and reduced costs.

Authors:  T M Young-Fadok; K HallLong; E J McConnell; G Gomez Rey; R L Cabanela
Journal:  Surg Endosc       Date:  2001-04-03       Impact factor: 4.584

6.  Relevance of outlier cases in case mix systems and evaluation of trimming methods.

Authors:  Francesc Cots; David Elvira; Xavier Castells; Marc Sáez
Journal:  Health Care Manag Sci       Date:  2003-02

7.  Modeling the cost-effectiveness of strategies for treating esophageal adenocarcinoma and high-grade dysplasia.

Authors:  Louisa G Gordon; Nicholas G Hirst; George C Mayne; David I Watson; Timothy Bright; Wang Cai; Andrew P Barbour; Bernard M Smithers; David C Whiteman; Simon Eckermann
Journal:  J Gastrointest Surg       Date:  2012-05-30       Impact factor: 3.452

8.  Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results.

Authors:  Theodoros Mantopoulos; Paul M Mitchell; Nicky J Welton; Richard McManus; Lazaros Andronis
Journal:  Eur J Health Econ       Date:  2015-10-07

9.  Methods to determine reimbursement rates for diagnosis related groups (DRG): a comparison of nine European countries.

Authors:  Jonas Schreyögg; Tom Stargardt; Oliver Tiemann; Reinhard Busse
Journal:  Health Care Manag Sci       Date:  2006-08

10.  The impact of home hospitalization on healthcare costs of exacerbations in COPD patients.

Authors:  Jaume Puig-Junoy; Alejandro Casas; Jaume Font-Planells; Joan Escarrabill; Carme Hernández; Jordi Alonso; Eva Farrero; Gemma Vilagut; Josep Roca
Journal:  Eur J Health Econ       Date:  2007-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.